Format

Send to

Choose Destination
Arch Intern Med. 2004 Jul 12;164(13):1405-12.

Management of alcohol withdrawal delirium. An evidence-based practice guideline.

Author information

1
Primary Care Service, Veterans Administration Medical Center, Manchester, NH 03104, USA. Michael.Mayo-Smith@med.va.gov

Erratum in

  • Arch Intern Med. 2004 Oct 11;164(18):2068. Dosage error in article text.

Abstract

BACKGROUND:

Alcohol withdrawal delirium is the most serious manifestation of alcohol withdrawal. Evidence suggests that appropriate care improves mortality, but systematic reviews are unavailable.

METHODS:

Articles with original data on management of alcohol withdrawal delirium underwent structured review and meta-analysis.

RESULTS:

Meta-analysis of 9 prospective controlled trials demonstrated that sedative-hypnotic agents are more effective than neuroleptic agents in reducing duration of delirium and mortality, with a relative risk of death when using neuroleptic agents of 6.6. Statistically significant differences among various benzodiazepines and barbiturates were not found. No deaths were reported in 217 patients from trials using benzodiazepines or barbiturates.

CONCLUSIONS:

Control of agitation should be achieved using parenteral rapid-acting sedative-hypnotic agents that are cross-tolerant with alcohol. Adequate doses should be used to maintain light somnolence for the duration of delirium. Coupled with comprehensive supportive medical care, this approach is highly effective in preventing morbidity and mortality.

PMID:
15249349
DOI:
10.1001/archinte.164.13.1405
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center